What is Rein Therapeutics Inc. (RNTX)?

Rein Therapeutics Inc. (RNTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of RNTX?

The current price of RNTX is $0.71. Prices are updated in real time on Stocks360.

What is RNTX's price-to-earnings (PE) ratio?

RNTX's trailing twelve-month PE ratio is -0.39, based on current price and earnings per share data available on Stocks360.

What is RNTX's market capitalization?

RNTX's market capitalization is $61,655,025.00, placing it in the small-cap tier.

Rein Therapeutics Inc. (RNTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.71

Market Cap

$61.66M

PE (TTM)

-0.39

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.35

Day Range

$0.66 – $0.72

52-wk Range

$0.54 – $2.18

Avg Volume

N/A

Volume

389.70K

Rein Therapeutics Inc. (RNTX) is a publicly traded company in the Healthcare sector. Latest price: $0.71. Market cap $61.66M. Trailing PE -0.39. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $1.55 2026-10-28 · $0.71 (-53.89%)

Earnings

Most Recent

Aug 14, 2026

EPS $-0.10 vs est. $-0.17

Beat by $0.07

Next Earnings

Nov 13, 2026

EPS estimate $-0.10

Proprietary Signals

Signal snapshot temporarily unavailable.

About Rein Therapeutics Inc.

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.39×
P/S (TTM)	0.00×
P/B	2.13×
P/FCF (TTM)	-3.27×
EV / EBITDA	-2.52×
EV / Sales	0.00×
Earnings Yield	-229.37%
Free Cash Flow Yield	-30.54%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$53.11M
Net Income (TTM)	-$141.42M
Free Cash Flow (TTM)	-$18.83M
Net Debt	-$8.54M
Working Capital	$31.74M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-234.45%
Return on Invested Capital	-36.37%